HomeNewsMost Popular NewsDo chlamydia infections affect birth outcomes?

Do chlamydia infections affect birth outcomes?

A study published in Lancet Infectious Disease determined if there is an association between chlamydia and negative birth outcomes.

Genital infections may be associated with negative birth outcomes. Chlamydia, a prevalent sexually transmitted infection, has been shown in some studies to cause birth issues. However, other studies have found that chlamydia infections have no effect on the baby.

In a recent study, researchers used existing data sets to look at three birth outcomes and their relationship to chlamydia infections. These three birth outcomes were unplanned preterm birth, stillbirths, and babies underweight for their gestational age.

Preterm birth was defined as a woman going into labour and giving birth before 37 weeks gestation, a baby underweight for its gestational age was defined as under being in the lowest 10% of birth weight by gestation and sex, and a stillbirth was defined as a baby that died in the womb after 20 weeks gestation. Although they were primarily interested in the direct link between these three outcomes and chlamydia, the researchers also analyzed them according to whether the mother had been tested before, during, or after pregnancy.

For the study, the researchers used data from the electoral roll and birth registrations of women of reproductive age in Western Australia. Inclusion in the study required the mother to be 15 years old or older, living in Western Australia, and for her baby to not be a twin. The data from these women was then associated with data from various health registries and databases to gain information on chlamydia test results, as well as maternal information and gestational information of the eligible women. The results were recently published in The Lancet Infectious Diseases.

Out of a total of 101,558 women included in the study, 3.9%, 9.6% and 0.7% experienced unplanned preterm birth, an underweight baby for its gestational age, and stillborns, respectively. There were 18.9% of women who received chlamydia testing before pregnancy, 20.9% received testing during pregnancy, and 60.2% did not get tested at all. Regardless of the chlamydia test results, the women tested before pregnancy had an increased risk of preterm birth and stillbirths, but a lower risk of having a baby that is underweight for its gestational age.

Spontaneous preterm births were present among 4.1% of women who tested negative for chlamydia before pregnancy and 5.5% of women who tested positive for chlamydia before pregnancy. Similarly, only 4.5% of women who tested negative and 6.2% of women who tested positive during pregnancy had unplanned preterm births.

Positive chlamydia test results during pregnancy were associated with a baby underweight for its gestational age. Conversely, there was no link between stillbirths and chlamydia status, and not enough data were present to analyze this relationship according to when the mother was tested. Young, non-Caucasians with low incomes had increased likelihoods for stillbirths, preterm labour, or having a baby underweight for its gestational age, regardless of chlamydia status or testing time.

Overall, the data analyses show the risk of spontaneous preterm birth, an underweight baby or stillbirth does not greatly increase with a chlamydia infection before pregnancy or during pregnancy. This is the largest study to date to evaluate the risk of chlamydia in pregnancy to birth outcomes. The authors identify the need for future research to evaluate the risk of treated and untreated chlamydia infections that are identified before or during pregnancy.

Written by Monica Naatey-Ahumah, BSc

Reference: Reekie, J., Roberts, C., Preen, D., Hocking, J.S., Donovan, B., Ward, J., and Liu,B.(2018). Chlamydia trachomatis and the risk of spontaneous preterm birth, babies who are born small for gestational age, and stillbirth: a population-based cohort study. The Lancet Infectious Diseases, 18(4), 452-460. https://doi.org/10.1016/S1473-3099(18)30045-8.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

ANKTIVA Boosts BCG for Bladder Cancer

The FDA has approved the immunotherapy-boosting drug, ANKTIVA, to be used with the existing immunotherapy drug, Bacillus Calmette-Guerin (BCG). This new therapy is a...

Joke Of The Day

Patient: Do you really think I need to see a heart specialist? Doctor: Not really, but your insurance will cover it, and he is a friend of...

ADVERTISE WITH US

error: Content is read-only and copy-protected.